Your browser doesn't support javascript.
loading
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.
Gawrzak, Sylwia; Rinaldi, Lorenzo; Gregorio, Sara; Arenas, Enrique J; Salvador, Fernando; Urosevic, Jelena; Figueras-Puig, Cristina; Rojo, Federico; Del Barco Barrantes, Ivan; Cejalvo, Juan Miguel; Palafox, Marta; Guiu, Marc; Berenguer-Llergo, Antonio; Symeonidi, Aikaterini; Bellmunt, Anna; Kalafatovic, Daniela; Arnal-Estapé, Anna; Fernández, Esther; Müllauer, Barbara; Groeneveld, Rianne; Slobodnyuk, Konstantin; Stephan-Otto Attolini, Camille; Saura, Cristina; Arribas, Joaquín; Cortes, Javier; Rovira, Ana; Muñoz, Montse; Lluch, Ana; Serra, Violeta; Albanell, Joan; Prat, Aleix; Nebreda, Angel R; Benitah, Salvador Aznar; Gomis, Roger R.
Afiliación
  • Gawrzak S; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Rinaldi L; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Gregorio S; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Arenas EJ; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Salvador F; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Urosevic J; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Figueras-Puig C; CIBERONC, Madrid, Spain.
  • Rojo F; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Del Barco Barrantes I; CIBERONC, Madrid, Spain.
  • Cejalvo JM; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Palafox M; Pathology Department, IIS-Fundación Jimenez Diaz, Madrid, Spain.
  • Guiu M; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Berenguer-Llergo A; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Symeonidi A; Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomèdiques Pi i Sunyer-IDIBAPS, Barcelona, Spain.
  • Bellmunt A; Experimental Therapeutics, Vall d'Hebron Insitute of Oncology, Barcelona, Spain.
  • Kalafatovic D; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Arnal-Estapé A; CIBERONC, Madrid, Spain.
  • Fernández E; Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Müllauer B; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Groeneveld R; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Slobodnyuk K; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Stephan-Otto Attolini C; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Saura C; Department of Pathology, Yale University School of Medicine, Yale, CT, USA.
  • Arribas J; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Cortes J; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Rovira A; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Muñoz M; Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Lluch A; Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Serra V; Department of Oncology, Vall d'Hebrón University Hospital, Barcelona, Spain.
  • Albanell J; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Prat A; CIBERONC, Madrid, Spain.
  • Nebreda AR; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Benitah SA; Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Gomis RR; ICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
Nat Cell Biol ; 20(2): 211-221, 2018 02.
Article en En | MEDLINE | ID: mdl-29358704
For many patients with breast cancer, symptomatic bone metastases appear after years of latency. How micrometastatic lesions remain dormant and undetectable before initiating colonization is unclear. Here, we describe a mechanism involved in bone metastatic latency of oestrogen receptor-positive (ER+) breast cancer. Using an in vivo genome-wide short hairpin RNA screening, we identified the kinase MSK1 as an important regulator of metastatic dormancy in breast cancer. In patients with ER+ breast cancer, low MSK1 expression associates with early metastasis. We show that MSK1 downregulation impairs the differentiation of breast cancer cells, increasing their bone homing and growth capacities. MSK1 controls the expression of genes required for luminal cell differentiation, including the GATA3 and FOXA1 transcription factors, by modulating their promoter chromatin status. Our results indicate that MSK1 prevents metastatic progression of ER+ breast cancer, suggesting that stratifying patients with breast cancer as high or low risk for early relapse based on MSK1 expression could improve prognosis.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteínas Quinasas S6 Ribosómicas 90-kDa / Factor de Transcripción GATA3 / Factor Nuclear 3-alfa del Hepatocito Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Animals / Female / Humans / Middle aged Idioma: En Revista: Nat Cell Biol Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteínas Quinasas S6 Ribosómicas 90-kDa / Factor de Transcripción GATA3 / Factor Nuclear 3-alfa del Hepatocito Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Animals / Female / Humans / Middle aged Idioma: En Revista: Nat Cell Biol Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido